Abstract:BACKGROUND: Preeclampsia, especially preterm preeclampsia and early-onset preeclampsia, is a life-threating pregnancy disorder, and the heterogeneity and complexity of preeclampsia make it difficult to predict risk and to develop treatments. Plasma cell-free RNA carries unique information from human tissue and may be useful for noninvasive monitoring of maternal, placental, and fetal dynamics during pregnancy. OBJECTIVE: This study aimed to investigate various RNA biotypes associated with preeclampsia in plasma and to develop classifiers to predict preterm preeclampsia and early-onset preeclampsia before diagnosis. STUDY DESIGN: We performed a novel, cell-free RNA sequencing method termed polyadenylation ligation-mediated sequencing to investigate the cell-free RNA characteristics of 715 healthy pregnancies and 202 pregnancies affected by preeclampsia before symptom onset. We explored differences in the abundance of different RNA biotypes in plasma between healthy and preeclampsia samples and built preterm preeclampsia and early-onset preeclampsia prediction classifiers using machine learning methods. Furthermore, we validated the performance of the classifiers using the external and internal validation cohorts and assessed the area under the curve and positive predictive value. RESULTS: We detected 77 genes, including messenger RNA (44%) and microRNA (26%), that were differentially expressed in healthy mothers and mothers with preterm preeclampsia before symptom onset, which could separate participants with preterm preeclampsia from healthy samples and that played critical functional roles in preeclampsia physiology. We developed 2 classifiers for predicting preterm preeclampsia and early onset preeclampsia before diagnosis based on 13 cell-free RNA signatures and 2 clinical features (in vitro fertilization and mean arterial pressure), respectively. Notably, both classifiers showed enhanced performance when compared with the existing methods. The preterm preeclampsia prediction model achieved 81% area under the curve and 68% positive predictive value in an independent validation cohort (preterm, n=46; control, n=151); the early-onset preeclampsia prediction model had an area under the curve of 88% and a positive predictive value of 73% in an external validation cohort (early-onset preeclampsia, n=28; control, n=234). Furthermore, we demonstrated that downregulation of microRNAs may play vital roles in preeclampsia through the upregulation of preeclampsia-relevant target genes. CONCLUSION: In this cohort study, a comprehensive transcriptomic landscape of different RNA biotypes in preeclampsia was presented and 2 advanced classifiers with substantial clinical importance for preterm preeclampsia and early-onset preeclampsia prediction before symptom onset were developed. We demonstrated that messenger RNA, microRNA, and long noncoding RNA can simultaneously serve as potential biomarkers of preeclampsia, holding the promise of prevention of preeclampsia in the future. Abnormal cell-free messenger RNA, microRNA, and long non coding RNA molecular changes may help to elucidate the pathogenic determinants of preeclampsia and open new therapeutic windows to effectively reduce pregnancy complications and fetal morbidity.

Expression of long non-coding RNA GAS5 by first trimester screening predicts the occurrence of gestational hypertension and pre-eclampsia

Long Non-coding RNA Gas5 Is Associated With Preeclampsia and Regulates Biological Behaviors of Trophoblast via MicroRNA-21

Polymorphism in Maternal HLA-DRB5 is Associated with the Risk of Preeclampsia in Chinese Population

[Expression of Gas6 in placenta and decidua tissues and its relationship with the pathogenesis of preeclampsia]

Bioinformatics-based Identification of Mirna-, Lncrna-, and Mrna-Associated Cerna Networks and Potential Biomarkers for Preeclampsia.

Identification and validation of an angiogenesis-related signature associated with preeclampsia by bioinformatic analysis

Evaluation of Circulating Placenta-Related Long Noncoding RNAs As Potential Biomarkers for Preeclampsia

Predicting preeclampsia by integrating maternal characteristics, mean arterial pressure and serum biomarkers at 15～20 gestational weeks

Single-Cell RNA Sequencing and Microarray Analysis Reveal the Role of Lipid-Metabolism-Related Genes and Cellular Immune Infiltration in Pre-Eclampsia and Identify Novel Biomarkers for Pre-Eclampsia

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Association Study Between GAS6 Gene Polymorphisms and Risk of Preeclampsia in Chinese Population

Early Detection of Preeclampsia Using Circulating Small non-coding RNA

Non-invasive preeclampsia prediction using plasma cell-free RNA signatures

A Potential Autophagy-Related-Gene Based Signature in Patients with Preeclampsia

Noninvasive Preeclampsia Prediction Using Plasma Cell-Free RNA Signatures

Bioinformatics identification and validation of maternal blood biomarkers and immune cell infiltration in preeclampsia: An observational study

Identifying Key Genes and Drug Screening for Preeclampsia Based on Gene Expression Profiles

IGFBP1 and Routine Laboratory Indicators for Early Prediction of Pre-Eclampsia in Chinese Population

Identification of gene signature markers in gestational hypertension and early-onset pre-eclampsia

Maternal Mid-Trimester Placental Growth Factor and Uterine Artery Doppler Velocimetry in Evolution of Pre-Eclampsia

Maternal Serum PLGF, PAPPA, Β-Hcg and AFP Levels in Early Second Trimester As Predictors of Preeclampsia